Viant (DSP) Q3 2025 earnings beat EPS estimates by 62% with strong profit growth, despite a slight revenue miss. The company also provided optimistic Q4 guidance.
TransAct (TACT) Q3 2025 earnings: Revenue slightly missed estimates, but the company achieved a key milestone by returning to profitability, beating EPS forecasts.
ProKidney (PROK) reports Q3 2025 results, beating EPS estimates. Key updates include strong Phase 3 trial enrollment and a confirmed FDA accelerated approval pathway for its kidney disease therapy.
Arcturus Q3 2025 results show a revenue miss but a smaller-than-expected loss. The company advances its CF and OTC programs, with cash extending into 2028.
The S&P 500 rose about 1.5% as implied volatility levels fell sharply. The VIX 1-Day dropped from 16.9 to open around 9—a big decline—before closing at 11.2.
Zentalis (ZNTL) beat Q3 2025 earnings estimates. The biotech firm has no revenue but a strong cash position, with key data for its lead drug, azenosertib, expected in late 2026.
Gemini Space Station's Q3 2025 results show revenue beat estimates, but a larger-than-expected loss sent the stock tumbling over 12% in after-hours trading.
Green Dot (GDOT) reported mixed Q3 2025 results, beating earnings estimates but slightly missing on revenue. The company also raised its full-year 2025 profit guidance, signaling confidence.
Gevo Q3 2025 earnings show strong revenue beat and positive EBITDA, despite a wider net loss. The company advances its sustainable fuel projects and carbon credit sales.
REPAY Holdings (RPAY) reported Q3 2025 results, missing both revenue and EPS estimates. The stock fell as revenue of $77.7M and EPS of $0.21 fell short of expectations.
Ambac Financial (soon Octave) beat Q3 2025 revenue estimates and posted a narrower loss, signaling progress in its strategic shift to a specialty insurance firm.
Mereo BioPharma (MREO) beat Q3 EPS estimates with a narrower loss. The clinical-stage company has cash into 2027 and key data for its lead drug expected soon.
ON24 (ONTF) beat Q3 2025 earnings and revenue estimates. The digital engagement platform also raised its full-year outlook and showed strong cash flow growth.
Theravance Biopharma (TBPH) reported Q3 2025 results, beating EPS estimates with a profit of $0.04. Revenue was slightly below forecasts. Lead drug YUPELRI achieved record sales.
Insight Molecular Dx (IMDX) stock fell 11.8% after missing Q3 2025 revenue and EPS estimates. The company remains focused on its FDA submission for the GraftAssureDx™ test.
DocGo's Q3 2025 results show a revenue miss but a narrower EPS loss. The stock fell as the company transitions away from migrant services, guiding for lower 2026 revenue.
Mobile Infrastructure (BEEP) reported mixed Q3 2025 results, missing revenue and earnings estimates. The company's net loss widened, but strategic growth in contract parking and a new $100M ABS provide a future roadmap.
Quest Resource (QRHC) posted mixed Q3 2025 results, beating revenue estimates but reporting a wider loss. The stock rose on the revenue beat and positive operational updates like debt reduction.
Identiv (INVE) Q3 2025 earnings: revenue slightly missed estimates, but the company beat on EPS with a smaller-than-expected loss, sending shares higher.
BCSF's Q3 2025 results show a mixed performance, with revenue missing estimates but core earnings covering its dividend. The market reaction was muted.
Natural Gas Services Group (NGS) reported mixed Q3 2025 results, beating earnings estimates but slightly missing on revenue. The company raised its full-year EBITDA guidance and highlighted a strong outlook for 2026.
